Neuromod Devices Limited

Neuromod Devices Limited is a global medical technology company specializing in tinnitus treatment through neuromodulation. The company developed and commercialized Lenire, the first and only FDA-approved bimodal neuromodulation device for tinnitus treatment. Lenire combines sound stimulation with electrical stimulation to target tinnitus through coordinated neural pathways and has demonstrated safety and efficacy across three large-scale independent clinical trials involving over 600 patients, with results published in peer-reviewed scientific journals. Neuromod holds 136+ neuromodulation patents for tinnitus treatment across 37 countries. The company operates a global distribution network with over 200 clinicians providing Lenire services across Europe and the United States, supported by more than 130 clinics. Neuromod maintains ISO 13485 quality standards and adheres to rigorous regulatory requirements. The company provides comprehensive practice enablement services including clinical training, commercial support, and an integrated Partner Platform that handles clinic onboarding, scalable operations, and patient care coordination. Manufacturing is industrialized with full supply chain redundancy. Neuromod serves ENT specialists, audiologists, and hearing care practitioners treating chronic tinnitus patients seeking FDA-cleared therapeutic alternatives.